A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics

The blood‐brain barrier (BBB) prevents the access of therapeutic antibodies to central nervous system (CNS) targets. The engineering of bispecific antibodies in which a therapeutic “arm” is combined with a BBB‐transcytosing arm can significantly enhance their brain delivery. The BBB‐permeable single‐domain antibody FC5 was previously isolated by phenotypic panning of a naive llama single‐domain antibody phage display library. In this study, FC5 was engineered as a mono‐ and bivalent fusion with the human Fc domain to optimize it as a modular brain delivery platform. In vitro studies demonstrated that the bivalent fusion of FC5 with Fc increased the rate of transcytosis (Papp) across brain endothelial monolayer by 25% compared with monovalent fusion. Up to a 30‐fold enhanced apparent brain exposure (derived from serum and cerebrospinal fluid pharmacokinetic profiles) of FC5‐compared with control domain antibody‐Fc fusions after systemic dosing in rats was observed. Systemic pharmacological potency was evaluated in the Hargreaves model of inflammatory pain using the BBB‐impermeable neuropeptides dalargin and neuropeptide Y chemically conjugated with FC5‐Fc fusion proteins. Improved serum pharmacokinetics of Fc‐fused FC5 contributed to a 60‐fold increase in pharmacological potency compared with the single‐domain version of FC5; bivalent and monovalent FC5 fusions with Fc exhibited similar systemic pharmacological potency. The study demonstrates that modular incorporation of FC5 as the BBB‐carrier arm in bispecific antibodies or antibody‐drug conjugates offers an avenue to develop pharmacologically active biotherapeutics for CNS indications.—Farrington, G. K., Caram‐Salas, N., Haqqani, A. S., Brunette, E., Eldredge, J., Pepinsky, B., Antognetti, G., Baumann, E., Ding, W., Garber, E., Jiang, S., Delaney, C., Boileau, E., Sisk, W. P., Stanimirovic, D. B., A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics. FASEB J. 28, 4764–4778 (2014). www.fasebj.org

[1]  Anirvan Ghosh,et al.  Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.

[2]  Daniel C. Liebler,et al.  Comparison of Protein Immunoprecipitation-Multiple Reaction Monitoring with ELISA for Assay of Biomarker Candidates in Plasma , 2013, Journal of proteome research.

[3]  C. Bowman,et al.  Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. , 2013, Current drug metabolism.

[4]  R. Fischer,et al.  With or Without Sugar? (A)glycosylation of Therapeutic Antibodies , 2013, Molecular Biotechnology.

[5]  G. Xiao,et al.  Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics , 2013, International journal of cell biology.

[6]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[7]  E. Brunette,et al.  Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. , 2013, Molecular pharmaceutics.

[8]  K. Scearce-Levie,et al.  Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier , 2013, Science Translational Medicine.

[9]  W. Pardridge,et al.  Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor , 2013, Biotechnology and bioengineering.

[10]  R. Thorne,et al.  Diffusion of macromolecules in the brain: implications for drug delivery. , 2013, Molecular pharmaceutics.

[11]  J. Ghersi-Egea,et al.  Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. , 2013, Molecular pharmaceutics.

[12]  A. Haqqani,et al.  Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells , 2013, Fluids and Barriers of the CNS.

[13]  M. von Zastrow,et al.  Regulation of µ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance , 2013, Pharmacological Reviews.

[14]  G. E. Vates,et al.  A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β , 2012, Science Translational Medicine.

[15]  A. Friedman,et al.  Pathophysiology of the Neurovascular Unit: Disease Cause or Consequence? , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  L. Wood,et al.  A Monoclonal Antibody-GDNF Fusion Protein Is Not Neuroprotective and Is Associated with Proliferative Pancreatic Lesions in Parkinsonian Monkeys , 2012, PloS one.

[17]  Y. Michotte,et al.  Using microdialysis to analyse the passage of monovalent nanobodies through the blood–brain barrier , 2012, British journal of pharmacology.

[18]  M. Christie,et al.  Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons , 2012, British journal of pharmacology.

[19]  Christilyn P. Graff,et al.  Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration , 2011, Journal of Pharmacology and Experimental Therapeutics.

[20]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[21]  A. Hartz,et al.  ABC transporters in the CNS - an inventory. , 2011, Current pharmaceutical biotechnology.

[22]  I. Wilhelm,et al.  In vitro models of the blood-brain barrier. , 2011, Acta neurobiologiae experimentalis.

[23]  J. Tanha,et al.  Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain* , 2011, The Journal of Biological Chemistry.

[24]  B. Meibohm,et al.  Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[25]  G. Sutherland,et al.  Kinetic analysis of novel mono‐ and multivalent VHH‐fragments and their application for molecular imaging of brain tumours , 2010, British journal of pharmacology.

[26]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[27]  W. Pardridge,et al.  Comparison of Blood-Brain Barrier Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF Fusion Protein in the Rhesus Monkey , 2009, Drug Metabolism and Disposition.

[28]  H. Revets,et al.  The development of nanobodies for therapeutic applications. , 2009, Current opinion in investigational drugs.

[29]  Koteshwara Mudigonda,et al.  A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system , 2009, Journal of Neuroscience Methods.

[30]  M. Christie,et al.  Two Distinct Mechanisms Mediate Acute μ-Opioid Receptor Desensitization in Native Neurons , 2009, The Journal of Neuroscience.

[31]  R. Béliveau,et al.  Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2 , 2008, Journal of neurochemistry.

[32]  가버 엘렌,et al.  Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto , 2008 .

[33]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[34]  H. Sprong,et al.  The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells , 2005, Journal of neurochemistry.

[35]  Danny D Shen,et al.  Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. , 2004, Advanced drug delivery reviews.

[36]  N. Joan Abbott,et al.  Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology , 2004, Neurochemistry International.

[37]  G. Pasternak,et al.  Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[38]  W. Pardridge,et al.  Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.

[39]  Jamshid Tanha,et al.  Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. , 2002, Journal of immunological methods.

[40]  J. Tanha,et al.  Selection of phage‐displayed llama single‐domain antibodies that transmigrate across human blood‐brain barrier endothelium , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Oitzl,et al.  A refined method for sequential blood sampling by tail incision in rats , 2000, Laboratory animals.

[42]  M. J. Coloma,et al.  Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor , 2000, Pharmaceutical Research.

[43]  P. Bjorkman,et al.  High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. , 1997, Biochemistry.

[44]  M. Radeke,et al.  Distribution of Intracerebral Ventricularly Administered Neurotrophins in Rat Brain and Its Correlation with Trk Receptor Expression , 1994, Experimental Neurology.

[45]  G. Mattson,et al.  A practical approach to crosslinking , 1993, Molecular Biology Reports.

[46]  W. Pardridge,et al.  Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.

[47]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[48]  J. Kornhuber,et al.  A method for repeated CSF sampling in the freely moving rat , 1986, Journal of Neuroscience Methods.

[49]  Charles Watson,et al.  Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight , 1985, Journal of Neuroscience Methods.

[50]  C. Patlak,et al.  Drainage of interstitial fluid from different regions of rat brain. , 1984, The American journal of physiology.

[51]  C. Patlak,et al.  Efflux of radiolabeled polyethylene glycols and albumin from rat brain. , 1981, The American journal of physiology.

[52]  S. Muyldermans,et al.  Introduction to heavy chain antibodies and derived Nanobodies. , 2012, Methods in molecular biology.

[53]  E. Stopa,et al.  The blood-cerebrospinal fluid barrier: structure and functional significance. , 2011, Methods in molecular biology.

[54]  A. Abulrob,et al.  Integrated platform for brain imaging and drug delivery across the blood-brain barrier. , 2011, Methods in molecular biology.

[55]  Jiunn H. Lin,et al.  CSF as a surrogate for assessing CNS exposure: an industrial perspective. , 2008, Current drug metabolism.

[56]  John F Kelly,et al.  Quantitative protein profiling by mass spectrometry using label-free proteomics. , 2008, Methods in molecular biology.

[57]  J. Tanha,et al.  Phage display technology for identifying specific antigens on brain endothelial cells. , 2003, Methods in molecular medicine.

[58]  Meindert Danhof,et al.  Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting , 2002, Clinical pharmacokinetics.

[59]  P. Hutson,et al.  A technique for repeated sampling of cerebrospinal fluid in freely moving rats and its uses. , 1984, Journal de physiologie.